{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:04:14Z","timestamp":1788991454426,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.cmi.2023.10.001","type":"journal-article","created":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T07:28:49Z","timestamp":1699082929000},"page":"732-737","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Alternative therapies against Mycobacterium abscessus infections"],"prefix":"10.1016","volume":"30","author":[{"given":"Ivana","family":"Palucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Delogu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2023.10.001_bib1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3390\/microorganisms7030090","article-title":"Mycobacterium abscessus: environmental bacterium turned clinical nightmare","volume":"7","author":"Lopeman","year":"2019","journal-title":"Microorganisms"},{"key":"10.1016\/j.cmi.2023.10.001_bib2","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41579-020-0331-1","article-title":"Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus","volume":"18","author":"Johansen","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.cmi.2023.10.001_bib3","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jcf.2021.02.002","article-title":"Beyond phenotype: the genomic heterogeneity of co-infecting Mycobacterium abscessus smooth and rough colony variants in cystic fibrosis patients","volume":"20","author":"Guti\u00e9rrez","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cmi.2023.10.001_bib4","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/S1473-3099(16)00070-0","article-title":"Tuberculosis\u2014advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers","volume":"16","author":"Wallis","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2023.10.001_bib5","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000490478","article-title":"Host directed therapies for tuberculosis: futures strategies for an ancient disease","volume":"63","author":"Palucci","year":"2018","journal-title":"Chemotherapy"},{"key":"10.1016\/j.cmi.2023.10.001_bib6","doi-asserted-by":"crossref","first-page":"660916","DOI":"10.3389\/fimmu.2021.660916","article-title":"Host-directed therapies: modulating inflammation to treat tuberculosis","volume":"12","author":"Krug","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2023.10.001_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3899\/jrheum.140097","article-title":"The spectrum of tuberculosis infection: new perspectives in the era of biologics","volume":"91","author":"Delogu","year":"2014","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.cmi.2023.10.001_bib8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/imr.12951","article-title":"Host-directed therapy to combat mycobacterial infections","volume":"301","author":"Kilin\u00e7","year":"2021","journal-title":"Immunol Rev"},{"key":"10.1016\/j.cmi.2023.10.001_bib9","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1080\/21505594.2020.1809961","article-title":"Sirtuin 3 is essential for host defense against Mycobacterium abscessus infection through regulation of mitochondrial homeostasis","volume":"11","author":"Kim","year":"2020","journal-title":"Virulence"},{"key":"10.1016\/j.cmi.2023.10.001_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02546-21","article-title":"Combined host- and pathogen-directed therapy for the control of Mycobacterium abscessus infection","volume":"10","author":"Poerio","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.cmi.2023.10.001_bib11","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/stem.2353","article-title":"A novel therapeutic approach using mesenchymal stem cells to protect against Mycobacterium abscessus","volume":"34","author":"Kim","year":"2016","journal-title":"Stem Cells"},{"key":"10.1016\/j.cmi.2023.10.001_bib12","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/INF.0000000000001780","article-title":"Compassionate nitric oxide adjuvant treatment of persistent mycobacterium infection in cystic fibrosis patients","volume":"37","author":"Yaacoby-Bianu","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2023.10.001_bib13","doi-asserted-by":"crossref","first-page":"1702127","DOI":"10.1183\/13993003.02127-2017","article-title":"Inhaled granulocyte-macrophage colony-stimulating factor for Mycobacterium abscessus in cystic fibrosis","volume":"51","author":"Scott","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cmi.2023.10.001_bib14","first-page":"3042","article-title":"Inhibition of transglutaminase 2 as a potential host-directed therapy against","volume":"10","author":"Palucci","year":"2019","journal-title":"Mycobacterium tuberculosis. Front Immunol"},{"key":"10.1016\/j.cmi.2023.10.001_bib15","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3390\/ijms24021203","article-title":"Cysteamine\/cystamine exert anti-Mycobacterium abscessus activity alone or in combination with amikacin","volume":"24","author":"Palucci","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cmi.2023.10.001_bib16","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1128\/AAC.00735-10","article-title":"Inhibition of bacterial multidrug resistance by celecoxib, a cyclooxygenase-2 inhibitor","volume":"55","author":"Kalle","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.10.001_bib17","doi-asserted-by":"crossref","first-page":"13491","DOI":"10.1038\/s41598-018-31590-4","article-title":"Adjunctive use of celecoxib with anti-tuberculosis drugs: evaluation in a whole-blood bactericidal activity model","volume":"8","author":"Naftalin","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.cmi.2023.10.001_bib18","article-title":"Eradication of Mycobacterium abscessus infection in cystic fibrosis with initiation of Elexacaftor\/Tezacaftor\/Ivacaftor","author":"McParland","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cmi.2023.10.001_bib19","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/jac\/dkr154","article-title":"Identification of antimicrobial activity among FDA-approved drugs for combating Mycobacterium abscessus and Mycobacterium chelonae","volume":"66","author":"Chopra","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2023.10.001_bib20","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1002\/med.21798","article-title":"Pipeline of anti-Mycobacterium abscessus small molecules: repurposable drugs and promising novel chemical entities","volume":"41","author":"Egorova","year":"2021","journal-title":"Med Res Rev"},{"key":"10.1016\/j.cmi.2023.10.001_bib21","doi-asserted-by":"crossref","first-page":"8533","DOI":"10.3390\/ijms22168533","article-title":"The antimalarial mefloquine shows activity against Mycobacterium abscessus, inhibiting mycolic acid metabolism","volume":"22","author":"Degiacomi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cmi.2023.10.001_bib22","doi-asserted-by":"crossref","first-page":"eabj3860","DOI":"10.1126\/scitranslmed.abj3860","article-title":"Therapeutic efficacy of antimalarial drugs targeting DosRS signaling in Mycobacterium abscessus","volume":"14","author":"Belardinelli","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cmi.2023.10.001_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00601-22","article-title":"A novel leucyl-tRNA synthetase inhibitor, MRX-6038, expresses anti-Mycobacterium abscessus activity in vitro and in vivo","volume":"66","author":"Wu","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.10.001_bib24","article-title":"Epetraborole is active against Mycobacterium abscessus","volume":"65","author":"Ganapathy","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.10.001_bib25","doi-asserted-by":"crossref","first-page":"6793","DOI":"10.3390\/ijms21186793","article-title":"Alternative and experimental therapies of Mycobacterium abscessus infections","volume":"21","author":"Meir","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cmi.2023.10.001_bib26","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41598-020-57844-8","article-title":"Effect of amoxicillin in combination with imipenem-relebactam against Mycobacterium abscessus","volume":"10","author":"Rlopeman","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.cmi.2023.10.001_bib27","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/jac\/dkz018","article-title":"Repurposing disulfiram to target infections caused by non-tuberculous mycobacteria","volume":"74","author":"Das","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2023.10.001_bib28","doi-asserted-by":"crossref","first-page":"11029","DOI":"10.3390\/ijms222011029","article-title":"Clomiphene citrate shows effective and sustained antimicrobial activity against Mycobacterium abscessus","volume":"22","author":"Lee","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cmi.2023.10.001_bib29","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s40265-019-01207-9","article-title":"Pretomanid: first approval","volume":"79","author":"Keam","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.cmi.2023.10.001_bib30","doi-asserted-by":"crossref","first-page":"1115530","DOI":"10.3389\/fcimb.2023.1115530","article-title":"Efficacy of PBTZ169 and pretomanid against Mycobacterium avium, Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum in BALB\/c mice models","volume":"13","author":"Zheng","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.cmi.2023.10.001_bib31","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01943-19","article-title":"Rifabutin is active against Mycobacterium abscessus in mice","volume":"64","author":"Dick","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.10.001_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00363-20","article-title":"Rifabutin is bactericidal against intracellular and extracellular forms of Mycobacterium abscessus","volume":"64","author":"Johansen","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.10.001_bib33","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00564-22","article-title":"In vitro and in vivo activity of gepotidacin against drug-resistant mycobacterial infections","volume":"66","author":"Ahmad","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.10.001_bib34","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev-med-080219-122208","article-title":"Phage therapy for antibiotic-resistant bacterial infections","volume":"73","author":"Hatfull","year":"2022","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.cmi.2023.10.001_bib35","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","article-title":"Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus","volume":"25","author":"Dedrick","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2023.10.001_bib36","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.cell.2022.04.024","article-title":"Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection","volume":"185","author":"Nick","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.cmi.2023.10.001_bib37","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/cid\/ciac453","article-title":"Phage therapy of Mycobacterium infections: compassionate use of phages in 20 patients with drug-resistant mycobacterial disease","volume":"76","author":"Dedrick","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.10.001_bib38","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.03431-20","article-title":"Mycobacterium abscessus strain morphotype determines phage susceptibility, the repertoire of therapeutically useful phages, and phage resistance","volume":"12","author":"Dedrick","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.cmi.2023.10.001_bib39","doi-asserted-by":"crossref","first-page":"dmm049159","DOI":"10.1242\/dmm.049159","article-title":"Mycobacteriophage-antibiotic therapy promotes enhanced clearance of drug-resistant Mycobacterium abscessus","volume":"14","author":"Johansen","year":"2021","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.cmi.2023.10.001_bib40","doi-asserted-by":"crossref","first-page":"eabb8699","DOI":"10.1126\/science.abb8699","article-title":"Stepwise pathogenic evolution of Mycobacterium abscessus","volume":"372","author":"Bryant","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.cmi.2023.10.001_bib41","doi-asserted-by":"crossref","first-page":"E4228","DOI":"10.1073\/pnas.1605477113","article-title":"Deletion of a dehydratase important for intracellular growth and cording renders rough Mycobacterium abscessus avirulent","volume":"113","author":"Halloum","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cmi.2023.10.001_bib42","doi-asserted-by":"crossref","first-page":"E10147","DOI":"10.1073\/pnas.1812984115","article-title":"MmpL8(MAB) controls Mycobacterium abscessus virulence and production of a previously unknown glycolipid family","volume":"115","author":"Dubois","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cmi.2023.10.001_bib43","doi-asserted-by":"crossref","first-page":"E1002","DOI":"10.1073\/pnas.1713195115","article-title":"Identification of genes required for Mycobacterium abscessus growth in vivo with a prominent role of the ESX-4 locus","volume":"115","author":"Laencina","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cmi.2023.10.001_bib44","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3390\/pathogens11090953","article-title":"Mycobacterium abscessus mutants with a compromised functional link between the type VII ESX-3 system and an iron uptake mechanism reliant on an unusual mycobactin siderophore","volume":"11","author":"Bythrow","year":"2022","journal-title":"Pathogens"},{"key":"10.1016\/j.cmi.2023.10.001_bib45","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3390\/pharmaceutics15020502","article-title":"Targeting siderophore-mediated iron uptake in M. abscessus: a new strategy to limit the virulence of non-tuberculous mycobacteria","volume":"15","author":"Mori","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.cmi.2023.10.001_bib46","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41564-022-01307-5","article-title":"Biotin-dependent cell envelope remodelling is required for Mycobacterium abscessus survival in lung infection","volume":"8","author":"Sullivan","year":"2023","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.cmi.2023.10.001_bib47","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41564-023-01330-0","article-title":"Mycobacterial biotin biosynthesis counters airway alkalinity","volume":"8","author":"Daher","year":"2023","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.cmi.2023.10.001_bib48","doi-asserted-by":"crossref","first-page":"151855","DOI":"10.1016\/j.scitotenv.2021.151855","article-title":"Antibacterial peptide RP557 increases the antibiotic sensitivity of Mycobacterium abscessus by inhibiting biofilm formation","volume":"807","author":"Li","year":"2022","journal-title":"Sci Total Environ"},{"key":"10.1016\/j.cmi.2023.10.001_bib49","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1080\/03601234.2012.669331","article-title":"In vitro effects of citrus oils against Mycobacterium tuberculosis and non-tuberculous Mycobacteria of clinical importance","volume":"47","author":"Crandall","year":"2012","journal-title":"J Environ Sci Health B"},{"key":"10.1016\/j.cmi.2023.10.001_bib50","doi-asserted-by":"crossref","first-page":"112095","DOI":"10.1016\/j.jep.2019.112095","article-title":"Ginger essential oil and fractions against Mycobacterium spp","volume":"244","author":"Baldin","year":"2019","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.cmi.2023.10.001_bib51","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1080\/14786419.2018.1509335","article-title":"In vitro\u201d activity of Melaleuca cajuputi against mycobacterial species","volume":"34","author":"Bua","year":"2020","journal-title":"Nat Prod Res"},{"key":"10.1016\/j.cmi.2023.10.001_bib52","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3390\/biom10030357","article-title":"Untargetted metabolomic exploration of the Mycobacterium tuberculosis stress response to cinnamon essential oil","volume":"10","author":"Sieniawska","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.cmi.2023.10.001_bib53","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.micpath.2017.11.002","article-title":"Antibiofilm activity of nanoemulsions of Cymbopogon flexuosus against rapidly growing mycobacteria","volume":"113","author":"Rossi","year":"2017","journal-title":"Microb Pathog"},{"key":"10.1016\/j.cmi.2023.10.001_bib54","doi-asserted-by":"crossref","first-page":"948","DOI":"10.3390\/antibiotics11070948","article-title":"Investigating the antituberculosis activity of selected commercial essential oils and identification of active constituents using a biochemometrics approach and in silico modeling","volume":"11","author":"Boussamba-Digombou","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2023.10.001_bib55","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.chest.2023.05.036","article-title":"Open-label trial of amikacin liposome inhalation suspension in Mycobacterium abscessus lung disease","volume":"164","author":"Siegel","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2023.10.001_bib56","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jcf.2019.05.013","article-title":"Clofazimine inhalation suspension for the aerosol treatment of pulmonary nontuberculous mycobacterial infections","volume":"18","author":"Banaschewski","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cmi.2023.10.001_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2022.102301","article-title":"Preclinical murine models to study lung infection with Mycobacterium abscessus complex","volume":"138","author":"Nicola","year":"2023","journal-title":"Tuberculosis (Edinb)."},{"key":"10.1016\/j.cmi.2023.10.001_bib58","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3389\/fimmu.2013.00098","article-title":"Modeling the Mycobacterium tuberculosis granuloma \u2013 the critical battlefield in host immunity and disease","volume":"4","author":"Guirado","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2023.10.001_bib59","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/mmi.14824","article-title":"Mycobacteria-host interactions in human bronchiolar airway organoids","volume":"117","author":"Iakobachvili","year":"2022","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.cmi.2023.10.001_bib60","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.3390\/antibiotics10121515","article-title":"Improving the drug development pipeline for mycobacteria: modelling antibiotic exposure in the hollow fibre infection model","volume":"10","author":"Maitra","year":"2021","journal-title":"Antibiotics (Basel)"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X2300486X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X2300486X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T20:38:40Z","timestamp":1728938320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X2300486X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1198743X2300486X"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2023.10.001","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alternative therapies against Mycobacterium abscessus infections","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2023.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}